New Hope for Alzheimers Treatment

There is now widespread agreement among research scientists and medical professionals that Alzheimer's Disease (AD) is a problem quickly growing to vast proportions. As the life expectancy of Americans continues to rise, increasing the percentage of the population over 65 years of age, so does the number of Alzheimer's cases.

It is currently estimated that people over 65 years of age have a 10% chance of developing Alzheimer's, while those over 85 have a 50% likelihood of developing AD, making it the leading cause of dementia among older people. Though the disease is associated primarily with memory loss, its effects also comprise a number of other severe disabilities, including changes in personality, disorientation, difficulty with speech and comprehension, and a lack of ability to move normally.

Consequently, most Alzheimer's patients require a great deal of care, costing society close to $100 billion annually. According to Christian Fritze, Ph.D., Director of the Antibody Products Division at Covance Research Products, "The impact of Alzheimer's Disease on our society will only increase as our population ages. The prevalence of the disease and disabling effects on the patient are significant by themselves. In addition we are becoming increasingly aware of the far-reaching effects on families, care-giver networks and the economics of our health care system. The drive for progress towards effective treatments by the research and drug development community is growing stronger every day."

A New Consensus

But recent developments in the medical research community do provide some hope. During the last two years, there has been a growing consensus among Alzheimer researchers about the cause of Alzheimer's disease, providing focus for scientists exploring the new treatment options.

The focus is on amyloid beta oligomers, a new wrinkle on an older hypothesis called the "amyloid cascade hypothesis". Widespread acceptance of this new conclusion is something of a milestone in the history of Alzheimer's research. As Dr. Fritze says, "The decades old quest for the causative agent in Alzheimer's Disease has recently focused on the precursors of amyloid plaques. These precursors are part of a bewildering array of processed (APP) Amyloid Precursor Protein) variants, Tau isoforms and secretase components that play a role in neuronal cytotoxicity and subsequent brain dysfunction."

Amyloid plaques are sticky protein deposits in the brain containing amyloid beta peptide. Researchers have associated the buildup of this plaque with Alzheimer's disease since its discovery in 1907. But despite the clear correlation, scientists were not sure what, exactly, spurred the onset of Alzheimer's Disease.

The hypothesis that amyloid beta accumulation in the brain is the major cause of Alzheimer's Disease1 has been the focus of much attention over the past decade. Although this hypothesis was the leading explanation for the cause of AD, it had several weaknesses. The most obvious problem with the theory was the fact that the buildup of amyloid beta peptides did not necessarily correspond with the severity of Alzheimer's symptoms.

However, in 19982 and in 20023, researchers proposed that it was not the amyloid beta plaques themselves that were neurotoxic ? and therefore the cause of Alzheimer's ? but rather precursors to amyloid beta plaques formed by smaller aggregates of amyloid beta. These new ideas are gaining widespread acceptance among the Alzheimer's research community, creating a consensus that had not existed before.

This new focus provides one more spur to action for Alzheimer's researchers, and underscores the need for further advancement. "The AD field demands sophisticated, highly-sensitive research tools to track these components and quantitate the existence of monomeric, oligomeric and fibrillar amyloid forms present in the progression of Alzheimer's disease," says Dr. Fritze.

Antibody Treatment

Two new studies, both released in October 20044, suggest that new treatment options may be on the horizon. The studies are the modification of one of two previous attempts using amyloid beta (Aβ) antibodies in the treatment of Alzheimer's Disease. The previous attempts, though not successful, did at least suggest new courses of action in Alzheimer's research and provided invaluable information for researchers.

In the first of the two previous attempts, researchers injected the antigen itself ? pieces of the beta amyloid protein that makes up amyloid plaque ? into mice, in the hopes that the injections would generate an immune (antibody) response against amyloid. Results were initially positive. The injected antigen produced Aβ antibodies and slowed the onset of the disease by decreasing Aβ levels. However, when tried on humans, the procedure led to meningoencephalitis (an inflammation of tissue around the brain) in some patients, and was therefore halted.

In the second attempt, a passive immunity therapy was tried in which antibodies to amyloid beta (not amyloid protein) were injected into mice, but hemorrhaging and inflammation ensued due to the high antibody doses required to be effective.

New Hope

But now there appears to be new hope for the use of antibodies as therapeutic agents for the treatment of Alzheimer's patients. In the first of the two new studies that appeared in October conducted by the National Institute for Longevity Sciences, NCGG, and the Center for Neurological Diseases, Brigham & Women's College, Harvard Institute of Medicine, researchers modified the first procedure. Concluding that the meningoenchaphalitis which occurred in some patients was caused by autoimmune T-cell activation, the researchers hoped to develop a vaccine that could minimize this T-cell activation while retaining the production of Aß antibodies.

To accomplish this they created an oral vaccine that attached Aß DNA to an adeno-associated virus vector, which served to mitigate T-cell activation. Thus they were able to decrease Aß levels in the brains of the mice and yet not activate T-cells to the degree they had before, greatly reducing the risk of meningoencephalitis.

In the other new study, conducted at the University of Illinois at Chicago, researchers succeeded in making the passive immunity protocol much safer. This they accomplished by changing the point of entry for the Aß antibodies. Rather than injecting the antibodies into the body of the mice, as was done previously, antibody was injected directly into the brain of the mice. Because the antibodies were injected directly into the brain, smaller doses were needed, and side effects were minimized.

The results of the above studies, and the potential for further optimized immunization strategies may prove to be watershed events in the history of Alzheimer's treatment.

Covance is a leading provider of innovative antibody products and custom antibody development services to the research community for Alzheimer's disease. Visit www.Covance.com for more in-depth information and to view the suite of products for Alzheimer's disease. Boris Predovich is Vice President of Immunology and Surgical Services at Covance Research Products.

Notes

1. J.A. Hardy, G.A. Higgins (1992), Science, 256:184-5.
2. M.P. Lambert et al (1998), Proc Natl Acad Sci, 95:6448-53.
3. D.M. Walsh et al (2002), Nature, 416:535-9.
4. Neelima B. Chauhan et al (2004), Journal of Neuroscience Research, 78, 5:732-741.
Hideo Hara et al (2004), Journal of Alzheimer's Disease, 6, 5:483-488.

R. L. Fielding writes on many health-related topics.

Crisis Looms for Florida Elder Care Services
Insurance News Net (press release), PA - 20 hours ago
... population growth in the elder segment, a complex mix of sometimes conflicting forces is dramatically altering the long-term care facilities market and ...

LTC123: The measure of greatness
Wareham Courier, MA - Oct 7, 2008
He will work to reform the financing of long-term care to protect seniors and families. He will work to improve the quality of elder care, including by ...

Core Benefits on the Rise
Multichannel News, NY - 5 hours ago
The ability to telecommute, health and wellness plans, assistance wiith adoption expenses and elder-care benefit plans have been very popular, said Scripps ...

Community Eldercare Services LLC Deploys Voice-Assisted Care to ...
MarketWatch - Oct 9, 2008
As part of its implementation, all 20 of Community Eldercare Services' facilities in Mississippi, Tennessee and Louisiana -- comprising more than 1000 ...
PointClickCare and Vocollect Healthcare Systems Announce New ... International Business Times
AccuNurse(R) Voice-Assisted Care Takes Interactive Care Delivery ... MarketWatch
PointClickCare and Vocollect Healthcare Systems Announce New ... MarketWatch
all 42 news articles

PSS World Medical's Rating Outlook Revised to Positive By S&P - Update
RTT News, NY - 12 hours ago
Moreover, physician practices and elder care business could experience reduced reimbursement beyond 2009. These pressures could lead to higher bad debt for ...
Standard & Poor's Revises Outlook for PSS World Medical, Inc. to ... MarketWatch
all 11 news articles

Hoeven wants to boost child care, elder care
Grand Forks Herald, ND - Oct 7, 2008
He also announced he is seeking an additional $17 million for increased home-based care for elderly North Dakotans and those who need care because of ...

Care available for elderly family members
Burlington Union, MA - 3 hours ago
Cooperative Elder Services, Inc, an Adult Day Health and Alzheimer’s Day program located at 37 B Street, Burlington, provides respite care and a safe, ...

Paul and Lori Hogan, Co-Founders of Home Instead Senior Care will ...
PR Web (press release), WA - Oct 8, 2008
Today, the Home Instead Senior Care franchise offices employ nearly 60000 trained CAREGivers who provide millions of hours of elder care services annually ...

Additional Allegations Filed Against Elder Care Operator
MarketWatch - Oct 3, 2008
... clients that it is operated in such a way that it meets the needs of its elderly and vulnerable adult residents by providing a certain standard of care. ...

Vintage visions: Aging care focus of politics
NewsOK.com, OK - Oct 8, 2008
He will work to improve elder care’s quality, including training more nurses and health care workers. Sen. John McCain has said there is a need to develop a ...

10 Tips to Keep a Family Caregiver from Losing Their Mind

Caring full time for a loved one can be a challenging task, and it takes... Read More

Caring for Aging Relatives

It happens somewhat slowly in the beginning, maybe with a small cough that gets worse... Read More

Solitary Confinement -- for Life

Sixty-five year old Arthur Jones served a self-imposed life sentence - in his own home.Arthur... Read More

Local Businesses Serving Seniors Prove Commitment to Quality Care

Good news! You no longer have to risk chance when it comes to selecting a... Read More

What About Tennesse Dept. of Human Services Abuse of the Elderly and Their Families?

PART I: Physical Abuse of the Elderly vs. Tennessee DHS Abuse of FamiliesDuring the week... Read More

Caregiving Across The Miles?Tips for Successful Long Distance Caregiving

Caring for a parent or a loved one is a difficult job. Your duties as... Read More

Strategies on Paying for Nursing Home Care and Medicaid

The decision to place your loved one into a nursing home is an extremely difficult... Read More

Scaling Down (almost) Painlessly

Moving to a smaller house or apartment in a retirement community almost always involves a... Read More

Alzheimers Care Giving While Maintaining Your Own Health

Just for a moment I want you to imagine that you are coming out of... Read More

Respiratory Help Is Available For Seniors With COPD

As HMOs Continue to Drop Coverage for Seniors - Now Over 500,000 Victims - Those... Read More